JP2023524130A5 - - Google Patents

Info

Publication number
JP2023524130A5
JP2023524130A5 JP2022567280A JP2022567280A JP2023524130A5 JP 2023524130 A5 JP2023524130 A5 JP 2023524130A5 JP 2022567280 A JP2022567280 A JP 2022567280A JP 2022567280 A JP2022567280 A JP 2022567280A JP 2023524130 A5 JP2023524130 A5 JP 2023524130A5
Authority
JP
Japan
Prior art keywords
complement
peptides
subject
protein
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022567280A
Other languages
English (en)
Japanese (ja)
Other versions
JP7849304B2 (ja
JP2023524130A (ja
Filing date
Publication date
Priority claimed from GBGB2006789.8A external-priority patent/GB202006789D0/en
Application filed filed Critical
Publication of JP2023524130A publication Critical patent/JP2023524130A/ja
Publication of JP2023524130A5 publication Critical patent/JP2023524130A5/ja
Application granted granted Critical
Publication of JP7849304B2 publication Critical patent/JP7849304B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022567280A 2020-05-07 2021-05-06 補体タンパク質の検出 Active JP7849304B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2006789.8 2020-05-07
GBGB2006789.8A GB202006789D0 (en) 2020-05-07 2020-05-07 Detection of complement proteins
PCT/EP2021/062077 WO2021224430A1 (en) 2020-05-07 2021-05-06 Detection of complement proteins

Publications (3)

Publication Number Publication Date
JP2023524130A JP2023524130A (ja) 2023-06-08
JP2023524130A5 true JP2023524130A5 (enExample) 2024-05-17
JP7849304B2 JP7849304B2 (ja) 2026-04-21

Family

ID=71134867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567280A Active JP7849304B2 (ja) 2020-05-07 2021-05-06 補体タンパク質の検出

Country Status (8)

Country Link
US (1) US20230400470A1 (enExample)
EP (1) EP4147057A1 (enExample)
JP (1) JP7849304B2 (enExample)
CN (1) CN115997127A (enExample)
AU (1) AU2021267650A1 (enExample)
CA (1) CA3177760A1 (enExample)
GB (1) GB202006789D0 (enExample)
WO (1) WO2021224430A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB202203627D0 (en) * 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders
JP2026501750A (ja) 2023-01-05 2026-01-16 コンプリメント・セラピューティクス・リミテッド 補体疾患を処置するための薬剤および方法
WO2025083211A1 (en) * 2023-10-20 2025-04-24 Institut National de la Santé et de la Recherche Médicale Use of factor h for the treatment of dementia
LU103244B1 (en) 2024-02-14 2025-08-14 Univ Hamburg Eppendorf Uke Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005211063A (ja) 2004-01-30 2005-08-11 Junko Maekuroshima ブレンドノニ茶
WO2008005455A2 (en) 2006-07-03 2008-01-10 The Johns Hopkins University Peptide antibody depletion and its application to mass spectrometry sample preparation
WO2009059321A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
GB0815576D0 (en) 2008-08-28 2008-10-01 Lucas & Co Analysis of glycated proteins
WO2016068616A1 (ko) 2014-10-29 2016-05-06 차의과학대학교 산학협력단 C3 또는 c1r 보체를 분비하는 태반 유래 세포 및 이를 포함하는 조성물
GB201709222D0 (en) 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
KR102775717B1 (ko) 2018-03-13 2025-03-06 암젠 인크 질량 분광 분석을 위한 폴리펩티드의 순차적 소화
WO2019215330A1 (en) 2018-05-10 2019-11-14 The University Of Manchester Methods for assessing macular degeneration

Similar Documents

Publication Publication Date Title
JP2023524130A5 (enExample)
Jian et al. Association between progranulin and Gaucher disease
Ahuja et al. Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy
Zhang et al. Dynamic changes of CX3CL1/CX3CR1 axis during microglial activation and motor neuron loss in the spinal cord of ALS mouse model
Leyhe et al. Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study
Toledo et al. Plasma amyloid beta measurements-a desired but elusive Alzheimer's disease biomarker
Bertram et al. TREM2 and neurodegenerative disease
US10888600B2 (en) Methods and agents for treating Alzheimer's disease
JP7260248B2 (ja) 細胞透過性抗体
Gos et al. Contribution of RIT1 mutations to the pathogenesis of Noonan syndrome: four new cases and further evidence of heterogeneity
JP2022519583A5 (enExample)
JP2017533889A5 (enExample)
Dunmore et al. 4PBA restores signaling of a cysteine-substituted mutant BMPR2 receptor found in patients with pulmonary arterial hypertension
JP7849304B2 (ja) 補体タンパク質の検出
JP2007521015A5 (enExample)
Chen et al. Clinical and molecular characterization of non-syndromic retinal dystrophy due to c. 175G> A mutation in ceroid lipofuscinosis neuronal 3 (CLN3)
JP2022513721A5 (enExample)
Katagiri et al. Compound heterozygous splice site variants in the SCLT1 gene highlight an additional candidate locus for Senior-Løken syndrome
JP2023543763A5 (enExample)
Wan et al. Long non-coding RNA H19 deficiency ameliorates bleomycin-induced pulmonary inflammation and fibrosis
Caron et al. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice
JP4820092B2 (ja) 転移のための新規な因子及びその使用
Wang et al. Novel mutations of the ALMS1 Gene in patients with Alström syndrome
Mankoč Ramuš et al. The GG genotype of erythropoietin rs1617640 polymorphism affects the risk of proliferative diabetic retinopathy in Slovenian subjects with type 2 diabetes mellitus: enemy or ally?
Li et al. DENND3 p. L708V activating variant is involved in the pathogenesis of hereditary hemochromatosis via the RAB12/TFR2 signaling pathway